U.S. markets close in 3 hours 19 minutes
  • S&P 500

    4,354.82
    -88.29 (-1.99%)
     
  • Dow 30

    34,327.67
    -541.70 (-1.55%)
     
  • Nasdaq

    14,580.01
    -389.96 (-2.60%)
     
  • Russell 2000

    2,244.34
    -36.67 (-1.61%)
     
  • Crude Oil

    74.77
    -0.68 (-0.90%)
     
  • Gold

    1,738.70
    -13.30 (-0.76%)
     
  • Silver

    22.49
    -0.21 (-0.92%)
     
  • EUR/USD

    1.1684
    -0.0018 (-0.15%)
     
  • 10-Yr Bond

    1.5220
    +0.0380 (+2.56%)
     
  • GBP/USD

    1.3539
    -0.0165 (-1.21%)
     
  • USD/JPY

    111.3820
    +0.4040 (+0.36%)
     
  • BTC-USD

    41,584.78
    -1,673.50 (-3.87%)
     
  • CMC Crypto 200

    1,029.45
    -27.69 (-2.62%)
     
  • FTSE 100

    7,028.10
    -35.30 (-0.50%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

Dynavax Closes Enrollment in Renal Disease Study on Heplisav-B

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Dynavax Technologies Corporation DVAX announced that it has reached the enrollment target in a phase I study evaluating hepatitis B vaccine, Heplisav-B in patients with end-stage renal disease undergoing hemodialysis.

The study is evaluating a four-dose regimen of Heplisav-B in patients who have previously not received any hepatitis B vaccine. The company expects final immunogenicity data from the study in the fourth quarter of 2020.

Please note that Heplisav-B is approved for prevention of infection caused by all known subtypes of hepatitis B virus in adults. Dynavax generates revenues primarily from the sale of Heplisav-B, its only marketed product. The vaccine generated sales of $10.5 million in the first quarter of 2020, representing growth of almost 87% year over year.

Shares of Dynavax have increased 2.8% year to date compared with the industry’s rally of 7.9%.

The company had announced a strategic restructuring in May last year to prioritize the vaccine business by focusing on Heplisav-B. The company reduced workforce and streamlined operations to focus on Heplisav-B’s commercialization. The company’s decision to focus on Heplisav-B seems to be benefiting its sales.

It is also exploring alternatives for its immuno-oncology portfolio.

Following its restructuring initiatives, the company’s near-term focus is on Heplisav-B sales execution, while it is assessing additional opportunities to leverage its proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG1018, and evaluating other opportunities for growth.

Meanwhile, the company has established multiple research collaborations leveraging CpG 1018 to support the development of coronavirus vaccines. Dynavax has filed patent applications for the use of CpG-1018 in the COVID-19 vaccine. Several of its collaboration partners have announced clinical studies to evaluate a potential COVID-19 vaccine, which uses CpG-1018 adjuvant. A successful development of any vaccine will likely boost Dynavax revenues through milestone payments.

Dynavax Technologies Corporation Price

 

Dynavax Technologies Corporation Price
Dynavax Technologies Corporation Price

Dynavax Technologies Corporation price | Dynavax Technologies Corporation Quote

Zacks Rank and Stocks to Consider

Dynavax currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Geron Corporation GERN, Applied Genetics Technologies Corp. AGTC and Axovant Sciences Ltd. AXGT. All of them carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Geron’s loss per share estimates have narrowed from 48 cents to 28 cents for 2020 and from 38 cents to 29 cents for 2021 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average beat of 11.41%.        

Applied Genetics’ loss per share estimates have narrowed from $2.32 to $2.05 for 2020 and from $2.01 to $1.80 for 2021 in the past 60 days. The company delivered a positive earnings surprise in two of trailing four quarters, with an average beat of 1.34%.        

Axovant’s loss per share estimates have narrowed from $2.74 to $2.59 for 2020 and from $2.40 to $2.30 for 2021 in the past 60 days. The company delivered a positive earnings surprise in all trailing four quarters, with average beat of 34.22%.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report
 
Geron Corporation (GERN) : Free Stock Analysis Report
 
Applied Genetic Technologies Corporation (AGTC) : Free Stock Analysis Report
 
Axovant Sciences Ltd. (AXGT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.